VEGETABLE EXTRACT, METHOD FOR PREPARATION THEREOF AND ITS APPLICATIONS IN HUMAN AND VETERINARY MEDICINE

Abstract: The invention relates to a biologically active plant extract to be obtained by means of a method comprising the following steps of: a) pressing a vegetable material to pulp; b) subjecting the obtained pulp to a cold or hot treatment with an aqueous or organic solvent; c) removing the solvent until a determined degree of concentration is obtained; and d) optional further purifying of the thus obtained extract by one or more of the following methods; thermocoagulation, purification with ammonium sulphate, precipitation, chromatography on gel or ion-exchange resin.

Description: VEGETABLE EXTRACT, METHOD FOR PREPARATION THEREOF AND ITS APPLICATIONS IN HUMAN AND VETERINARY MEDICINE The present invention relates to new vegetable extracts, to their method of preparation and to their application in biotechnology and therapy, in particular due to their activity as cell growth- and growth- inhibit - ing factor. Plants often possess unsuspected therapeutic properties or constituents active as such. Particularly for the treatment of disorders which are difficult to treat, such as cancer and the like, plants are a potenti- al source of medicines. According to the present invention it has now been found, unexpectedly, that extracts which are biologically active can be prepared from plants, in particular vegetables containing glucide, protein, glycoprotein and terpene. For this purpose can be used vegetables such as potatoes, radish, turnip, beet, carrot, Jerusalem artichoke, sweet potato, rape, cucumber, pumpkin, courgette, tomato and the like. This list is not exhaustive. The extracts according to the invention are prepared in accordance with the following successive phases of : pressing the chosen vegetables to pulp; cold or hot treatment of the obtained pulp with an aqueous or organic solvent; - evaporating the solvent until a determined degree of concentration is obtained; optional further purifying of the thus obtained extract by one or more of the following methods such as thermocoagulation, purification with ammonium sulphate, precipitation, chromatography on gel or ion-exchange resin. A method of extraction which makes it possible to obtain three fractions having a determined activity has already been described in the French patent applica- tion FR-A-2 732 347 in the name of the company BIO MEDIA. The text of this application should be deemed as interpolated herein. According to the invention the extracts are purified still further, which has resulted in 16 molecules of the type glucide, protein, glycoprotein, terpene ' and peptide with molecular weights of 5,000, 7,500, 10,000, 12,000, 15,000, 20,000, 30,000, 40,000, 65,000, 82,000, 105,000, 130,000, 180,000, 200,000, 220,000, 250,000 daltons. All these molecules are readily soluble in water. These molecules can be obtained by further purifying the extract by chromatography on Q hyper DTM20- gel . 11 molecules are hereby obtained which elute at 0.0- 9 M, 0.15 M, 0.21 M, 0.25 M, 0.32 M, 0.45 M. 0.52 M, 0.70 M, 0.78 M, 0.85 M, 1.02 M NaCl. In the eluate of the column are situated the low-molecular constituents which can be further purified by chromatography on a second column based on QMA-gel. Five fractions were eluted at 0.05 M, 0.08 M, 0.12 M, 0.20 M and 0.27 M NaCl. Of the 16 different constituents obtained in this manner, the activity was determined as described in the examples . The toxicological and pharmacological studies described in the examples show the absence of toxicity of the compounds according to the invention, as well as their significant properties. The 14 molecules with mitogenic activity according to the invention can each be used as such or in different concentrations for different purposes, such as the manufacture of culture media for research and diagno- sis, for the production of molecules and vaccines for therapeutic use for human or animal medicine, or for cosmetic use. The five molecules which stimulate multiplication of micro-organisms can advantageously be used in the field of fermentation culture media, for the production of micro-organisms or of molecules for human and animal therapeutics, cosmetics or the agribusiness. The three molecules which have an effect on the metabolism will advantageously be administered in human and animal medicine in the case of weight deficiency or growth problems, or for bacteriological diagnostics. The two molecules, which have a cell-inhibiting activity, will advantageously be administered as anti- tumour agents and anti-cancer agents due to their cyto- static capacity. The invention will be further illustrated in the following non-limiting examples. EXAMPLES EXAMPLE 1 Isolation of active substances 1000 grams of a fresh, healthy pumpkin is crushed in order to obtain a fine puree. The puree obtained in this manner is treated for two hours with 500 grams of cold water. The paste (El) obtained is then either centrifuged or filtered to collect the pulp (E2) . The thus obtained extract is then purified by thermocoagulation in the presence of alcohol, caprylic acid, acetic acid and ammonium sulphate. After centrifu- gation the supernatant is recovered, and subsequently subjected to ultrafiltration in order to eliminate parti- cular salts and to obtain the correct concentration of filtrate . With chromatographic purification on Q hyper DTM20-gel of the thus obtained concentrate, 11 molecules are obtained which elute at 0.09 M, 0.15 M, 0.21 M, 0.25 M, 0.32 M, 0.45 M, 0.52 M, 0.70 M, 0.78 M, 0.85 M, 1.02 M NaCl. Reference will be made in the following to the different fractions on the basis of the concentration at which they elute. The lower molecular weights are situated in the eluate when the column is loaded. They are purified on a second column on QMA-gel and eluted at 0.05 M, 0.08 M, 0.12 M, 0.20 M and 0.27 M NaCl. EXAMPLE 2 Activity The molecules isolated in Example 1 exhibit a ~ high mitogenic capacity for all animal or human cells, with the exception of the molecules which are isolated at 0.32 M on Q hyper DTM20-gel and at 0.12 M on QMA-gel, which have a significant cell growth- inhibiting activity. EXAMPLE 3 Toxicoloqical study Tests performed both in vivo and in vitro show the low toxicity and good tolerance of the active ingre ¬ dients according to the invention. The cellular toxicity in vitro was determined using neutral red and MTT. At a dose of 600 μg/ml no toxicity was detected in the culture medium. The following in vivo tests were carried out. All molecules displaying mitogenic activities were tested on mice. This study demonstrated the absence of toxicity. The intraperitoneal injection of 0.5 ml of a 100 g/1 solution of each of these molecules on two groups of 24 male animals and 24 female animals caused no mortality after seven days . The same tests were performed with the same doses using the molecules which inhibit the cell growth. At the beginning of the experiment an average weight loss of 3-4% in the treated animals was observed. This was the case for both the females and the males. Four to five days after injection the animals resumed their normal growth, which demonstrates the non-toxicity of the molecules according to the invention. EXAMPLE 4 Pharmacological study Results of the pharmacological tests reported here show the significant properties of the active ingredient according to the invention. 1. Mitogenic activity The tests were performed on stocks of CRFK- and VERO-cells while making use of NUNC-plates with 6 wells and HAM F12 medium. The medium was strewn with 200,000 cells/ml. Each molecule was tested in cell culture relative to the controls consisting of only HAM F12 and HAM F12 + 10% foetal calf serum (FCS) in doses varying from 0.025 g/1 to 4 g/1. For each molecule the best concentration range was determined in respect of activity. The average activities lie between 0.05 g/1 and 0.05 g/1. The detected rate of multiplication of the cells varies between 3 and 5, depending on the tested molecule, i.e. at a starting quantity of 200,000 cells/ml, 600,000 to 1,000,000 cells/ml are formed. The rate of multiplication is comparable with the values obtained with the SVF-cells: 900,000 to 1,000,000 cells/ml. The mitogenic capacity of the molecules accor- ding to the invention was subsequently tested on more than 120 cell lines referred to in the ATCC, or in pri o- culture, animal, eukaryotic, human or diploid cells. In addition to their activity on the cell lines, it was observed that the molecules which eluted at 0.09 M, 0.15 M, 0.70 M, 0.85 M and 1.02 M likewise exhibit a considerable multiplying capacity on micro-organisms. Tests performed on Lactobacillus thus showed an increase in biomass of 30% in 24 hours relative to the control . 2. Inhibiting activity In tests performed under the same conditions, the molecules which eluted at 0.32 M on the Q Hyper DTM 20-column and 0.12 M on the QMA-column produced a total inhibition of the cell growth at doses between 0.5 g/1 and 1 g/1. These two molecules likewise inhibited the growth of the complete panel of tumour cells which is required by the NCI (62 stocks) . 3. Effect on the metabolism in vivo This study was carried out with the molecules which eluted at 0.21 M, 0.45 M on the Q Hyper DTM 20- column and at 0.20 M on the QMA-column. Different groups of 24 male mice and 24 female mice received 0.5 ml of a 100 g/1 solution of the molecule for testing. The molecules of the invention caused an average weight increase of 8,25% in both the male and female mice relative to the control groups, which only received an injection of 0.5 ml of a 100 g/1 solution of sodium chloride.

Claims: CLAIMS 1. Biologically active plant extract to be obtained by means of a method comprising the following steps of : a) pressing a vegetables material to pulp; b) subjecting the obtained pulp to a cold or hot treatment with an aqueous or organic solvent; c) removing the solvent until a determined degree of concentration is obtained; and d) optional further purifying of the thus obtained extract by one or more of the following methods: thermocoagulation, purification with ammonium sulphate, precipitation, chromatography on gel or ion-exchange resin . 2. Extract as claimed in claim 1, which is obt- ained from a vegetable chosen from potatoes, radish, turnip, beet, carrot, Jerusalem artichoke, sweet potato, rape, cucumber, pumpkin, courgette and tomato. 3. Biologically active compound to be obtained by further chromatographic purification of the extract as claimed in claim 1 or 2 on a Q hyper DTM20-gel chromatography column, eluting the column and subsequently collecting fractions which elute at determined concentrations of the eluent. 4. Biologically active compound as claimed in claim 3 which elutes at 0.09 M NaCl. 5. Biologically active compound as claimed in claim 3 which elutes at 0.15 M NaCl. 6. Biologically active compound as claimed in claim 3 which elutes at 0.21 M NaCl. 7. Biologically active compound as claimed in claim 3 which elutes at 0.25 M NaCl. 8. Biologically active compound as claimed in claim 3 which elutes at 0.32 M NaCl. 9. Biologically active compound as claimed in claim 3 which elutes at 0.45 M NaCl. 10. Biologically active compound as claimed in claim 3 which elutes at 0.52 M NaCl. 11. Biologically active compound as claimed in claim 3 which elutes at 0.70 M NaCl. 12. Biologically active compound as claimed in claim 3 which elutes at 0.78 M NaCl. 13. Biologically active compound as claimed in claim 3 which elutes at 0.85 M NaCl. 14. Biologically active compound as claimed in claim 3 which elutes at 1.02 M NaCl. 15. Biologically active compound to be obtained by further guiding the extract as claimed in claim 1 or 2 over a Q hyper DTM20-gel chromatography column, subsequently further purifying the eluate thereof on a QMA-gel chromatography column, eluting the column and subsequently collecting fractions which elute at determined concentrations of the eluent. 16. Biologically active compound as claimed in claim 15 which elutes at 0.05 M NaCl. 17. Biologically active compound as claimed in claim 15 which elutes at 0.08 M NaCl. 18. Biologically active compound as claimed in claim 15 which elutes at 0.12 M NaCl. 19. Biologically active compound as claimed in claim 15 which elutes at 0.20 M NaCl. 20. Biologically active compound as claimed in claim 15 which elutes at 0.27 M NaCl. 21. Biologically active compound as claimed in claims 4-7, 9-14, 16, 17, 19 and 20 for use as mitogen for eukaryotic cells. 22. Biologically active compound as claimed in claims 8 and 18 for use as cell growth- inhibiting agent. 23. Biologically active compound as claimed in claims 6, 9 and 19 for use as agent for stimulating the metabolism. 24. Biologically active compound as claimed in claims 4, 5, 11, 13 and 14 for use as mitogen for microorganisms . 25. Combination of one or more of the biologically active compounds as claimed in claims 4-7, 9-14, 16, 17, 19 and 20 for use as mitogen for eukaryotic cells . 26. Combination of one or more of the biologically active compounds as claimed in claims 8 and 18 for use as cell growth- inhibiting agent. 27. Combination of one or more of the biologically active compounds as claimed in claims 4, 5, 11, 13 and 14 for use as mitogen for micro-organisms. 28. Method for manufacturing a vegetable extract with a biological activity which consists of influencing cell growth, wherein the method comprises of: a) pressing a vegetable material to pulp; b) subjecting the obtained pulp to a cold or hot treatment with an aqueous or organic solvent; c) removing the solvent until a determined degree of concentration is obtained; and d) optional further purifying of the thus obtained extract by one or more of the following methods: thermocoagulation, purification with ammonium sulphate, precipitation, chromatography on gel or ion-exchange resin. 29. Method as claimed in claim 28, characteri- zed in that a) the treatment of the obtained pulp is carried out with cold water, b) the thus obtained material is concentrated by centrifugation or filtration, c) a thermocoagulation is subsequently performed in the presence of alcohol, caprylic acid, acetic acid and ammonium sulphate, d) the thus obtained extract is centrifuged, e) the supernatant is subjected to ultrafiltra- tion to obtain the extract. 30. Method as claimed in claim 28 or 29, further comprising of subjecting the extract to a chromato- graphic separation on a Q hyper DTM20-gel and eluting the column with a gradient of NaCl . 31. Method as claimed in claim 28 or 29, further comprising of " guiding the extract over a Q hyper DTM20-gel chromatography column and subsequent chromatographic separation of the eluate thereof on a column with QMA-gel and eluting of the column with a gradient of NaCl. 32. Medication for human or veterinary use, comprising at least one of the following constituents: an extract as claimed in claim 1 or 2 , biologically active compounds as claimed in claims 3-24 or combinations as claimed in claims 25-27. 33. Culture medium, comprising at least one of the following constituents: an extract as claimed in claim 1 or 2 , biologically active compounds as claimed in claims 3-24 or combinations as claimed in claims 25-27.

Inventors: GILLESSEN HUBERT JEAN MARIE FR, GILLESSEN, HUBERT, JEAN, MARIE, FRANCOIS
Applicants: FEVA N V, GILLESSEN HUBERT JEAN MARIE FR, FEVA N.V., GILLESSEN, HUBERT, JEAN, MARIE, FRANCOIS
Application year: 1998
Main classification: A61K35
IPC codes: A61K31, A61K36, A61P3, A61P43, C07G99, C12N1, C12N5